BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration

Behind BMS' focus on top-tier growth, as with other pharma giants, is a quest to recoup the billions of dollars in sales it stands to lose as aging blockbuster drugs head for the proverbial “patent cliff” by losing exclusivity in the U.S. and other key markets. BMS has laid groundwork for rebuilding its pipeline over the past year through a series of collaborations and acquisitions. The post BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration appeared first on GEN - Genetic Engineering and Biotechnology News .